List of Excipients in Branded Drug CYTOMEL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	CYTOMEL	liothyronine sodium	54868-5058	CALCIUM SULFATE
Physicians Total Care Inc	CYTOMEL	liothyronine sodium	54868-5058	GELATIN
Physicians Total Care Inc	CYTOMEL	liothyronine sodium	54868-5058	STARCH, CORN
Physicians Total Care Inc	CYTOMEL	liothyronine sodium	54868-5058	STEARIC ACID
Physicians Total Care Inc	CYTOMEL	liothyronine sodium	54868-5058	SUCROSE
Physicians Total Care Inc	CYTOMEL	liothyronine sodium	54868-5058	TALC

CYTOMEL Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 12, 2026

CYTOMEL is an immediate-release liothyronine sodium tablet marketed by Pfizer for oral thyroid hormone replacement. Its commercial opportunity is concentrated in generic substitution, low-dose manufacturing, excipient optimization, and differentiated formulations rather than in new-molecule exclusivity. The product is an old FDA-approved drug with no meaningful contemporary composition-of-matter patent barrier identified in the FDA’s public product records. [1][2]

What is CYTOMEL and which excipients does it contain?

CYTOMEL contains liothyronine sodium, the sodium salt of the synthetic thyroid hormone triiodothyronine, or T3. The product is supplied as 5 mcg, 25 mcg, and 50 mcg immediate-release tablets. [1]

The U.S. prescribing information identifies the following inactive ingredients:

Excipient	Functional role
Calcium sulfate	Diluent and tablet-body former
Corn starch	Binder, disintegrant, and filler
Gelatin	Binder
Stearic acid	Lubricant
Sucrose	Binder, filler, and taste-masking aid
Talc	Glidant and anti-adherent

The excipient system is conventional and low-cost. It supports standard wet granulation or related compression processes, but it does not create a significant product differentiation barrier. The principal technical challenge is the extremely low active dose, particularly at 5 mcg. A small absolute error in API distribution can produce a large relative potency deviation.

CYTOMEL tablet colors differ by strength. Colorants and other strength-specific formulation details should be confirmed against the current FDA labeling and product-specific inactive-ingredient records before a development or regulatory filing. [1][3]

What formulation patents protect CYTOMEL?

No active, commercially significant formulation patent protection is identified in the FDA Orange Book records associated with CYTOMEL’s legacy liothyronine sodium tablet product. [2]

The current product protection profile is therefore driven primarily by:

• FDA approval of the reference product;
• manufacturing know-how;
• dose uniformity controls;
• analytical methods;
• product-specific bioequivalence strategy;
• brand recognition and prescriber familiarity.

The listed excipients are widely used pharmaceutical materials. Calcium sulfate, starch, gelatin, stearic acid, sucrose, and talc are not proprietary to Pfizer and are available from multiple qualified suppliers. A generic manufacturer could use the same excipients, substitute pharmacopeial equivalents, or develop a different excipient platform subject to quality and bioequivalence requirements.

A formulation patent could still create commercial value if it covered a material improvement, such as:

• improved content uniformity at 5 mcg;
• reduced degradation of liothyronine;
• enhanced tablet dissolution;
• reduced sensitivity to humidity or oxidation;
• dye-free tablets;
• preservative-free liquid dosage forms;
• orally disintegrating or chewable tablets;
• modified release;
• pediatric or geriatric administration formats.

Such claims would protect the improvement, not the underlying CYTOMEL molecule.

When does CYTOMEL lose exclusivity?

CYTOMEL’s principal FDA exclusivity period expired decades ago. The product is based on an old active ingredient and is subject to generic competition through the abbreviated new drug application, or ANDA, pathway. [1][4]

Exclusivity category	CYTOMEL position
New chemical entity exclusivity	Expired or inapplicable
Five-year NCE exclusivity	Not available for this legacy product
Three-year clinical-investigation exclusivity	No current protection identified
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No current protection identified
Reference-product patent barrier	No material active listing identified in current public Orange Book records
Generic pathway	ANDA, subject to FDA requirements

The absence of active listed patents does not eliminate all launch risk. Generic developers must still establish pharmaceutical equivalence, demonstrate bioequivalence, satisfy current good manufacturing practice requirements, and manage the narrow-dose accuracy problem.

What is the Orange Book status of CYTOMEL?

CYTOMEL is an FDA-approved reference product associated with NDA 006461. The Orange Book identifies approved products, therapeutic equivalence ratings, patent listings, and exclusivity information. [2]

A generic liothyronine sodium tablet may be eligible for an “AB” therapeutic-equivalence rating if it satisfies FDA requirements and is approved against the relevant reference product. Therapeutic-equivalence status can support pharmacy-level substitution under state law, although substitution rules vary by jurisdiction.

The main commercial implications are:

1. No apparent blocking patent estate for the legacy immediate-release tablet.
2. Generic manufacturers can compete on price and supply reliability.
3. A differentiated dosage form may require a separate 505(b)(2) strategy rather than a conventional ANDA.
4. A product with a materially different route, release profile, or dosage form may not qualify for automatic substitution.

How strong is the CYTOMEL patent estate?

The CYTOMEL patent estate is weak as a barrier to conventional generic entry but may remain relevant as a source of formulation and manufacturing know-how.

Patent category	Strategic assessment
Composition of matter	No practical protection for the legacy active ingredient
Core tablet composition	No meaningful current barrier identified
Immediate-release dosage form	Vulnerable to ANDA competition
Manufacturing process	Potentially protectable, but ordinarily avoidable through non-infringing processes
Low-dose content uniformity	Potential area for new improvement patents
Alternative dosage forms	Stronger opportunity for new, separately protected products
Method of use	Limited blocking value where the underlying thyroid-replacement uses are established
Trade secrets	Potential value in blending, granulation, assay, and stability controls

Patent strength should be assessed separately from regulatory difficulty. Liothyronine is technically challenging at microgram strengths even though the patent estate is old. A well-controlled manufacturing process can therefore create a commercial advantage without providing long-term legal exclusivity.

What excipient strategy is best for a CYTOMEL generic?

The most defensible strategy is to optimize for content uniformity, stability, dissolution, and patient tolerability while minimizing unnecessary formulation changes.

Strategy 1: Use the reference-like excipient platform

A generic manufacturer can reproduce the conventional excipient architecture using calcium sulfate, starch, gelatin, stearic acid, sucrose, and talc.

Advantages include:

• Lower development risk;
• Familiar compaction behavior;
• Straightforward excipient qualification;
• Lower cost of goods;
• Reduced risk of unexpected dissolution differences;
• Easier justification of formulation similarity.

The weakness is limited differentiation. Multiple manufacturers can pursue a similar approach.

Strategy 2: Replace gelatin and sucrose

A gelatin-free and sucrose-free tablet could target patients with dietary, religious, allergy, or excipient-preference concerns. Potential alternatives include:

• Microcrystalline cellulose;
• Crospovidone;
• Croscarmellose sodium;
• Hypromellose;
• Povidone;
• Mannitol;
• Dibasic calcium phosphate.

The replacement must preserve low-dose uniformity and tablet robustness. A simple excipient substitution may change powder segregation, granule density, dissolution, and stability.

Strategy 3: Develop a direct-compression platform

Direct compression can reduce processing steps and eliminate wet-granulation variability. It requires a highly uniform API premix and excipients with suitable flow and compactibility.

For 5 mcg liothyronine sodium, the API represents a very small fraction of the tablet mass. A controlled geometric dilution or engineered premix may be more important than the choice between direct compression and granulation. Process controls should focus on:

• API particle-size distribution;
• Blend segregation;
• Sampling-plan design;
• Blend hold time;
• Compression-force variability;
• Tablet weight and assay correlation;
• Cleaning validation at low-dose carryover levels.

Strategy 4: Use a protective or moisture-resistant system

Liothyronine products require stability assessment under relevant temperature and humidity conditions. A protective film coat, high-barrier bottle, desiccant, or unit-dose blister may improve shelf life and supply-chain robustness.

Packaging can be commercially valuable where the tablet itself is difficult to improve. A blister presentation may also support adherence and reduce dispensing errors across three strengths.

Strategy 5: Develop an orally disintegrating or liquid product

A liquid or orally disintegrating liothyronine product could address patients who have difficulty swallowing tablets. It could also support pediatric and geriatric use.

The technical risks include:

• Dose uniformity across the container;
• Adsorption to packaging;
• Chemical stability in aqueous media;
• Microbial control;
• Preservative tolerability;
• Administration-device accuracy;
• Storage conditions;
• Greater risk of medication errors.

A liquid product would likely require a 505(b)(2) application if it relies on the established liothyronine safety and efficacy record but introduces a substantially different formulation or dosage form. [4]

What manufacturing and IP barriers exist for generic CYTOMEL?

The principal manufacturing barrier is not access to the excipients. It is reliable distribution of a microgram-level dose throughout a compressed tablet.

A commercially viable process should establish:

• A validated premix or granulation method;
• Tight assay and content-uniformity specifications;
• Robust blend sampling;
• In-process tablet-weight controls;
• Dissolution comparability;
• Stability under accelerated and long-term conditions;
• Controls for API segregation and electrostatic behavior;
• Separate manufacturing controls for 5 mcg, 25 mcg, and 50 mcg strengths.

Potential patent claims could focus on a defined premix ratio, particle-size range, granulation endpoint, excipient combination, coating system, or packaging configuration. Process patents are commercially useful only if the process is difficult to design around and produces measurable product advantages.

Which companies are challenging or competing with CYTOMEL?

The market includes the branded CYTOMEL product and generic liothyronine sodium tablets approved through the ANDA pathway. FDA approval records and the Orange Book are the authoritative sources for current applicants, manufacturers, therapeutic-equivalence ratings, and marketing status. [2][3]

Competition is likely to occur across four dimensions:

Competitive factor	Commercial effect
Unit price	Drives pharmacy and payer substitution
Supply continuity	Important because thyroid products are chronic-use medicines
Strength availability	5 mcg availability can influence physician preference
Dosage-form convenience	Creates differentiation beyond price

A generic with all three strengths, reliable supply, and a reference-like formulation can compete effectively. A differentiated product may obtain higher net pricing but faces greater regulatory and development costs.

What Paragraph IV challenges and litigation affect CYTOMEL?

No material, current Paragraph IV litigation or settlement arrangement is identified as a central barrier to the legacy CYTOMEL immediate-release tablet market in the cited FDA records. [2][5]

For an old product with no significant active Orange Book patent listing, a Paragraph IV strategy is less important than a Paragraph I or III certification, depending on the patent record and applicant’s legal position. Litigation risk could arise if a new formulation patent were listed for an authorized generic, reformulated product, or 505(b)(2) product.

Any future litigation would most likely involve:

• A newly issued formulation patent;
• A manufacturing-process patent;
• A patent covering an alternative dosage form;
• Trade-secret allegations;
• Regulatory exclusivity disputes.

How does CYTOMEL compare with levothyroxine products?

CYTOMEL is liothyronine, or T3. Levothyroxine products contain synthetic thyroxine, or T4. They are not direct formulation substitutes even though both are used in thyroid hormone replacement.

Attribute	CYTOMEL	Levothyroxine
Active ingredient	Liothyronine sodium	Levothyroxine sodium
Hormone	T3	T4
Common dosage scale	Micrograms	Micrograms
Immediate clinical effect	More rapid	Longer conversion and duration
Market size	Smaller	Much larger
Generic competition	Established	Extensive
Formulation sensitivity	High	High
Commercial whitespace	Alternative delivery and low-dose precision	Stability, excipient consistency, and branded formulations

The commercial market for a new liothyronine formulation is smaller than the levothyroxine market but may support premium positioning where dosing precision, administration convenience, or excipient restrictions matter.

What commercial opportunities exist for CYTOMEL excipients?

The strongest opportunities are:

1. A low-cost generic with robust 5 mcg content uniformity.
2. A gelatin-free and sucrose-free tablet.
3. A dye-free strength presentation.
4. A moisture-protected blister package.
5. An orally disintegrating tablet for swallowing-impaired patients.
6. A stable oral solution with a calibrated dosing device.
7. A combination or co-packaged thyroid replacement regimen, subject to clinical and regulatory requirements.
8. Contract manufacturing of validated low-dose thyroid tablets.
9. Excipient premixes engineered for microgram-dose uniformity.
10. A 505(b)(2) product using a differentiated delivery system.

Revenue exposure for the incumbent is tied to brand retention and the size of the liothyronine market, while generic entrants face a lower-price, volume-driven business. A formulation innovation can improve margins only if it creates a clinically meaningful or operationally measurable benefit that supports non-substitutable positioning.

Key Takeaways

• CYTOMEL is an immediate-release liothyronine sodium tablet available in 5 mcg, 25 mcg, and 50 mcg strengths.
• Its labeled excipients are conventional: calcium sulfate, corn starch, gelatin, stearic acid, sucrose, and talc.
• No material active patent barrier is identified for the legacy immediate-release tablet in current public FDA product records.
• The principal technical challenge is microgram-dose content uniformity, especially at 5 mcg.
• Generic competition is primarily an ANDA and manufacturing-execution issue.
• The best formulation opportunities involve gelatin-free, sucrose-free, dye-free, moisture-protected, orally disintegrating, or liquid products.
• A materially different dosage form would likely require a 505(b)(2) regulatory strategy.
• New IP is more likely to arise from low-dose manufacturing, stability, packaging, or alternative dosage forms than from the conventional tablet excipient system.

FAQs About CYTOMEL Excipients and Commercial Opportunities

Can a generic CYTOMEL use different excipients?

Yes. A generic manufacturer may use different inactive ingredients if the formulation meets FDA requirements, remains suitable for the intended route, and demonstrates pharmaceutical equivalence and bioequivalence.

Is liothyronine sodium a biologic requiring biosimilar approval?

No. Liothyronine sodium is a synthetic small-molecule drug. Generic products are generally regulated through the ANDA pathway, not the biosimilar pathway.

Does CYTOMEL have a narrow therapeutic index?

Thyroid hormone products require careful dosing and quality control because modest dose differences can affect clinical response. Regulatory assessment should address assay, content uniformity, dissolution, and bioequivalence at each strength.

Could a new CYTOMEL liquid receive five years of exclusivity?

A new liquid formulation would not ordinarily receive new chemical entity exclusivity because liothyronine is an established active ingredient. A 505(b)(2) product could potentially receive three-year exclusivity for qualifying new clinical investigations, subject to FDA requirements. [4]

Is the CYTOMEL brand protected by a formulation trade secret?

Public FDA labeling does not establish whether Pfizer maintains undisclosed manufacturing know-how. Trade-secret protection depends on confidential process information, not on the public excipient list.

References

1. U.S. Food and Drug Administration. (2024). CYTOMEL (liothyronine sodium) tablets: Prescribing information. Pfizer Laboratories.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. Center for Drug Evaluation and Research.

3. U.S. National Library of Medicine. (2024). DailyMed: CYTOMEL- liothyronine sodium tablet. National Library of Medicine.

4. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2024). Paragraph IV drug product and patent information resources. Center for Drug Evaluation and Research.